Publish Date : 02-Dec-2013
Pacific Edge has inked a deal with a large national provider network in the USA, Stratose, to provide Cxbladder to patients through its large network of payers and providers.
Stratose, contracts with nearly 850,000 direct and affiliate healthcare providers and provides a medical network solution to nearly 8.6 million Americans through its client base comprising of insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans.
For Pacific Edge, this is the third deal signed by national provider network organisations who contract with medical doctors, hospitals, and other health care providers who have convenanted with an insurer or a third-party administrator to provide health care to insured patients.
Deals with national provider network organisations serves as a major component in Pacific Edge's commercial launch of Cxbladder in the United States, said, Pacific Edge Chief Executive Officer David Darling.
He added, "The endorsement of these agencies provides a clear commercial process linking providers and payers and signals to clinicians across the United States the availability of Cxbladder. The addition of Stratose along with FedMed and ACPN now provides network coverage to a significant pool of American people giving commercial access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test, all of which are particularly appealing to US healthcare professionals, patients, and insurers alike."
Through its wholly owned subsidiary Pacific Edge Diagnostics USA (PEDUSA), Pacific Edge, has secured the first commercial sales of Cxbladder in the US and is currently processing commercial samples, collected using its proprietary Urine Sampling System, at its custom built laboratory in Hershey, Pennsylvania.
Jackie Walker, Chief Executive Officer PEDUSA, said, "Our sales and marketing teams are now focussed on the clinicians who are treating the largest number of bladder cancer patients to ensure they fully understand the benefits of Cxbladder."
"In addition, we are working with large commercial payers and the Centre for Medicare and Medicaid Services (CMS), which provides healthcare insurance to approximately 150 million people. Other large urology customers being targeted include the large Integrated Healthcare Systems, the Veterans Administration (VA), and Large Urology Group Practices (LUGS), who are the point of contact for many patients presenting with haematuria (blood in the urine) which is an early indicator of possible bladder cancer."
Go to previous page
